Poly Medicure Limited · NSE:POLYMED
Poly Medicure — Q2 FY27 Earnings Presentation
34 slides from Poly Medicure's earnings presentation, Nov 5, 2026
Slide 1: Submission of Investor's Presentation to exchanges
Poly Medicure Limited Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate, Phase-Ill, New Delhi - 110 020 (INDIA) ) :» IPOLYMED T: +91 -11- 33550700, 47317000 E: [email protected] W: polymedicure.com CIN : L40300DL1995PLC066923 Date: osu, November, 2026 Scrip Code: - 531768 Seri p Code:- POL
Slide 2: Investor Presentation: Q2 & H1 FY27
Investor Presentation : Q2 & H1 FY27 1 Nov 5, 2026 ) I ;
Slide 3: Disclaimer
Disclaimer -. :. JPOLYMED This presentation has been prepared by Poly Medicure Limited (the "Company"), content of which was compiled from sources believed to be reliable for informational purposes only and are based on information regarding the Company and the economic, regulatory, market and other
Slide 4: Company Overview
Company Overview
Slide 5: Polymed at a Glance
Polymed at a Glance -. :. JPOLYMED Largest* Listed Medical Devices Player in India I Largest Exporter of Medical Consumables Figs in Rs. Crs unless specified PRODUCT PORTFOLIO ,- ' ■. -~~ i 125+ ~ Medical 15 225+ ~. Manufacturing ' .~ ' ~ ; f ~ •') Safety IV Cannula Pref~;~::tine ~;~~~ec:;~t r;~~e~:
Slide 6: Polymed Flywheel
Polymed Flywheel -. :. JPOLYMED Integrated business model serving customers globally Clinical Engagement In-House Product R&D • 60+ clinical experts; • 25-30 new product launches annually • 4,000+ annual customer • 90+ R&D professionals engagement programs globally Manufacturing, Packaging and Distr
Slide 7: Diversified Segment and Geographic Mix
Diversified Segment and Geographic Mix -. :. JPOLYMED Rising contribution from New Segments I Deepening Presence in the Indian Market Segmental Revenue Mix Figs in Rs. Crs unless specified PORTFOLIO MIX Particulars l l l l l l l l l l l l l l l l l cAGR(23-26) 24% 37% Infusion Therapy 771 925 1,012
Slide 8: Moving up the value Chain
Moving up the value Chain -. :. JPOLYMED From essential consumables to advanced Medical Technologies 2025 ORTHOPAEDICS 2024 2018 2019 CRITICAL CARE CARDIOLOGY r r RENAL CARE 1997 Acquired Citieffe INFUSION THERAPY Entered cardiology in 2024 Over time to create a Launched DES in India in 2025 compreh
Slide 9: A 30-year compounding story
A 30-year compounding story- Growth Engine Just warming up -. :. JPOLYMED Proven yesterday. Scaling today. Defining tomorrow. G --------• ------------------ • ---------------------------►• 0 0 POLYMED 1.0 POLYMED 2.0 POLYMED 3.0 Foundation Inflection Ascent FY 1996-2020 FY 2021-2026 FY 2027 onwards
Slide 10: Polymed 1.0 (1996 to 2020): Foundation
Polymed 1.0 (1996 to 2020): Foundation -. :. JPOLYMED Resiliently built a global medical device platform with equity infusion of ~INR 54mn* ~25 years I Dedicated Focus I Bootstrapped From ~INR 5.4 Cr* IPO in 1996 built a globally competent infusion therapy platform Growth Funded by Internal Accruals
Slide 11: Polymed 2.0 (2021 to 2026): Inflection
Polymed 2.0 (2021 to 2026): Inflection -. :. JPOLYMED The inflection: capital, capacity, categories, countries - all scaling in parallel INR 14 Bn Institutional Equity Raised I Portfolio Expansion Growth Capital utilized towards capacity expansion, deeper penetration in Renal & Critical Care, alongs
Slide 12: Polymed 3.0 (2027 onwards): Ascent
Polymed 3.0 (2027 onwards): Ascent -. :. JPOLYMED The next chapter isn't incremental - it's exponential! 2.0x Revenue I Industry-leading margins I Globalization of the Business Model Climb the Tech Ladder • Double R&D spend " @ • ~ Business Expansion 2 upcoming plants ~. • Globalize high-complexity
Slide 13: Plan1 Health - Oncology focused Platform in Europe
Plan1 Health - Oncology focused Platform in Europe -. :. JPOLYMED Since 1995 I Italy I Acquired 100.0o/o in 2019 I EV ~Euro 4.2 Mn D WHATWEACQUIRED? fJ WHY WE ACQUIRED? EJ SYNERGIES REALISED ■ Entry into Critical Care segment ■ Integrated developer & seller of 2.2x 6.4x +890BPS ■ Access to clinical
Slide 14: PendraCare Group - Unique Cardiology Catheter Platform
PendraCare Group - Unique Cardiology Catheter Platform -. :. JPOLYMED Since 2011 I Netherlands I Acquired 90.0% in 2025 I EV: Euro 18.8 Mn ~·~ 50+ 1,150 m 2 3,800 m 2 ·11··I 65+ ■•■ ,.,, Countnes . ••• 50+ ,_,. Distributors II Cleanroom 3 Leased Facilities A! 1.5M+ ¥w Capacity/year I Employees A Uni
Slide 15: Citieffe - Fully integrated supplier of Trauma Implants
Citieffe - Fully integrated supplier of high-quality Trauma Implants -. :. JPOLYMED Since 1962I Italy I Acquired 100.0o/o in 20251 EV -Euro 31.0 Mn ,., ~·""" 30+ ••■ Countries 25+ Distributors -~ GIIIID 45 Patents 2,100 m 2 2 manufacturing facilities 85.0o/o+ Sales from countries with direct presenc
Slide 16: Robust Financial Performance
Robust Financial Performance -. :. JPOLYMED Q Margino/o ---- Revenue from operations (INR Cr) ---- Gross Profit (INR Cr) 1,115 ---- 1,376 19% 1,670 1,875 s 709 ---- 8 893 22.o/o 81,114 81,278 FV23 FY24 FY25 FV26 FV23 FY24 FY25 FV26 ---- ---- Operating EBITDA (INR Cr) PAT (INR Cr) s ----s s 361 2.0%
Slide 17: Strong Promoters and Experienced Leadership Team
Strong Promoters and Experienced Leadership Team -. :. JPOLYMED Promoters Experienced Leadership Team Mr. Himanshu Baid Mr. Alessandro Balboni Mr. Sujit Gupta (Managing Director) (Non-Executive Non-Independent Director) (Senior Vice President & Head International Co-founder of Poly Medicure, Mr. Bai
Slide 18: Robust Governance Framework
Robust Governance Framework -. :. JPOLYMED Non-Executive Board Mr. Devendra Raj Mehta Mr. Vishal Gupta (Chairman, Non-Executive Non-Independent Director) (Non-Executive Independent Director) A seasoned IAS officer and former Chairman of SEBI, Mr. Mehta Mr. Vishal Gupta is the Managing Director of As
Slide 19: Awards & Accolades
Awards & Accolades -. :. JPOLYMED Mr Himanshu Said-Visionary Mr Rishi Baid- Healthcare Leader Himanshu Baid, MD, Poly Himanshu Baid, MD, Poly Service Provider of the Year - Healthcare Entrepreneurship of the Year by India Health Next Medicure, Healthcare Medicure Healthcare Medical Devices Award by
Slide 20: Towards our Commitment to a Sustainable Future
Towards our Commitment to a > Reduced approx. 2,998.31 tCO2e of Scope 2 emissions co.) > Approximately 25.44% of total energy cl > Approx. 70% facilities are certified under vee consumption sourced from renewable ISO 14001:2015 energy. > Well-being health assessments ts) > Sustainable Beport for 1,1
Slide 21: Financial Results & Key Updates - Q2 & H1 FY27
Financial Results & Key Updates - Q2 & Hl FY27
Slide 22: Key Updates
Key Updates -. :. JPOLYMED ■ Medyneo (Subsidiary in Brazil) operationalisation on track; first shipment dispatched in October • Established a direct UK presence to capture opportunities under the India-UK FTA ■ Clinical deployment is improving month on month: DES -1 SK units (Oct 2026),lntravascular
Slide 23: Standalone Financial Performance Summary Q2 & H1 FY27
Standalone Financial Performance Summary Q2 & H1 FY27 -. , IPOLYMED Figs in Rs. Crs unless specified I Margin,% I Revenue Gross Profit Operating EBITDA1 _ _ __, 17.2% . - - - ~ ~ - - - 1 15.8% f - - - ~ ~ - -----i 20.3% t - -- ~ i ,------------ Q2 FY27 488.3 336.3 133.9 416.5 111.3 290.5 I I I I Q2F
Slide 24: Consolidated Financial Performance Summary Q2 & H1 FY27
Consolidated Financial Performance Summary Q2 & H1 FY27 -. , IPOLYMED Figs in Rs. Crs unless specified Revenue Gross Profit Operating EBITDA1 _ _ _ _ , 32.0% >--- - ~ - -----i 20.1% ..___ ~ ------------, i Q2 FY27 580.5 406.9 139.1 443.9 308.2 115.8 .-----1-;6- 442.3 Q2FY26 Q2FY27 Q2FY26 Q2FY27 Q2FY
Slide 25: Financial Performance Analysis
Financial Performance Analysis
Slide 26: Standalone Financial Performance Summary
Standalone Financial Performance Summary -. :. JPOLYMED Figs in Rs. Crs unless specified Particulars Q2FY27 Q2 FY26 YoY Growth o/o H1 FY27 H1 FY26 YoY Growth o/o Revenue from Operations 488.3 416.5 17.2% 919.4 800.6 14.8% -Domestic 171.8 140.9 22.0% 317.8 266.5 19.3% - International 313.1 272.9 14.7
Slide 27: Consolidated Financial Performance Summary
Consolidated Financial Performance Summary -. :. JPOLYMED Figs in Rs. Crs unless specified Particulars Q2 FY27 Q2 FY26 YoY Growth o/o H1 FY27 H1 FY26 YoY Growth o/o Revenue from Operations 580.5 443.9 30.8% 1,105.9 847.1 30.6% -Domestic 171.8 140.9 22.0% 317.8 266.5 19.3% - International 405.3 300.3
Slide 28: Consolidated Sales Performance Analysis (1/2)
Consolidated Sales Performance Analysis(112) -. , IPOLYMED Figs in Rs. Crs unless specified Consolidated Organic Particulars Q2 FY27 Q2 FY26 VoYGrowth % Q2 FY27 YoYGrowth % Domestic 171.8 140.9 22.0% 171.8 22.0% International 405.3 300.3 35.0% 339.2 13.6% Other Operating Revenue 3.3 2.8 18.4% 3.3 18
Slide 29: Consolidated Sales Performance Analysis (2/2)
Consolidated Sales Performance Analysis(212) -. , IPOLYMED Figs in Rs. Crs unless specified Consolidated Organic Particulars H1 FY27 H1 FY26 YoYGrowtho/o H1 FY27 YoYGrowtho/o Domestic 317.8 266.5 19.3% 317.8 19.3% International 781.5 575.4 35.8% 643.1 12.1% Other Operating Revenue 6.6 5.2 26.4% 6.6
Slide 30: Segment Wise Sales Performance Analysis
Segment Wise Sales Performance Analysis -. , IPOLYMED Figs in Rs. Crs unless specified Consolidated Particulars Q2 FY27 Q2 FY26 YoYGrowth % H1 FY27 H1 FY26 YoYGrowth% Infusion Therapy 283.7 254.1 11. 7% 541.6 487.4 11.1% Orthopaedics 42.7 NA 91.9 NA Renal 50.6 42.3 19.6% 93.8 87.2 7.5% Cardiology 27
Slide 31: Balance Sheet Summary and Working Capital Analysis
Balance Sheet Summary and Working Capital Analysis -. , IPOLYMED Figs in Rs. Crs unless specified Figs in Rs. Crs unless specified Consolidated As at Sep 30, As at Mar 31, Particulars 2026 2026 Particulars As at Sep 30, 2026 As at March 31, 2026 Debtors 559 531 Total Shareholders Funds 3,307.7 3,149
Slide 32: Cash Flow Summary
Cash Flow Summary -. :. JPOLYMED Figs in Rs. Crs unless specified Particulars H1 FY27 EBITDA 265.7 Other operating income an d non cash expense 36.2 Tax Paid (49.7) Operating Cash Flow befo re WC Changes 252.3 Investment in Working Ca pital Changes in Inventory (78.3) Changes in Debtors (39.7) Chang
Slide 33: Shareholding Pattern as on 30th Sep 2026
Shareholding Pattern as on 30th Sep 2026 -. :. JPOLYMED Top 10 Institutional Shareholders Bodies Corporate, \ Sr. No Name % Shareholding 2.99% 1 Quant Mutual Fund 4.6% Any Other, 0.16% ~ 2 Lighthouse 2.3% 3 Axis Max Life Insurance 2.1 o/o Insurance 4 UTI Asset Management 1.9% Companies, 2.33% 5 Vang
Slide 34: Thank You
Thank You For any investor related queries reach us at: [email protected]